Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan’s Teijin Pharma Gout Drug TMX-67 Gains EMEA Positive Opinion

This article was originally published in PharmAsia News

Executive Summary

Teijin Pharma received a positive opinion from the Europe Medicines Agency for gout drug TMX-67 through its licensee for Europe, Ipsen. An oral, once-daily drug, TMX-67 (febuxostat) is a novel xanthine oxidase inhibitor with a different structure than allopurinol, the only available gout drug developed 40 years ago. Teijin views IMX-67 as a way to expand into overseas markets. It also plans to resubmit an application for approval in Japan. Additional Phase III trials are being conducted in the U.S., and trials are also being conducted in Korea. After obtaining European approval, Ipsen plans to sell the drug under the name Adenuric.(Click for more-Japanese language

You may also be interested in...

Guardant Health Expects FDA Approval Of Liquid Biopsy Test Will Strengthen Coverage, Adoption

Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.

Finance Watch: CureVac’s IPO Is Ready For Launch

Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m. 

US FDA's Hahn Promotes Provider Role In Boosting Public Confidence In COVID-19 Products

Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts